Targeted treatment with drugs that are selective inhibitors of the production of cytokines involved in severe drug-related toxicity, such as tocilizumab, can significantly modify the clinical outcomes and allow the rapid resumption of anti-melanoma therapy.
![[This page as RDF]](http://data.gesis.org/somesci/static/rdf-icon.gif){kind=icon}